+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Fesoterodine"

Global Overactive Bladder Treatment Market by Drug Therapy (Anticholinergic, BOTO, Darifenacin), Disease Type (Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity), Distribution - Forecast 2024-2030 - Product Thumbnail Image

Global Overactive Bladder Treatment Market by Drug Therapy (Anticholinergic, BOTO, Darifenacin), Disease Type (Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity), Distribution - Forecast 2024-2030

  • Report
  • March 2024
  • 194 Pages
  • Global
From
Overactive Bladder Treatment (OAB) Market by Drug type ( Anticholinergic (Solifenacin, Oxybutynin, Tolterodine, Darifenacin), Mirabegron), Botox, Neuromodulation, Disease Type (Idopathic OAB and Neurogenic OAB) and Region - Global Forecasts to 2027 - Product Thumbnail Image

Overactive Bladder Treatment (OAB) Market by Drug type ( Anticholinergic (Solifenacin, Oxybutynin, Tolterodine, Darifenacin), Mirabegron), Botox, Neuromodulation, Disease Type (Idopathic OAB and Neurogenic OAB) and Region - Global Forecasts to 2027

  • Report
  • July 2022
  • 203 Pages
  • Global
From
South & Central America Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Pharmacotherapy and Disease Type - Product Thumbnail Image

South & Central America Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Pharmacotherapy and Disease Type

  • Report
  • January 2023
  • 124 Pages
From
Middle East & Africa Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - Product Thumbnail Image

Middle East & Africa Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis

  • Report
  • January 2023
  • 134 Pages
  • Middle East, Africa
From
Asia Pacific Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - Product Thumbnail Image

Asia Pacific Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis

  • Report
  • January 2023
  • 160 Pages
  • Asia Pacific
From
North America Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - Product Thumbnail Image

North America Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis

  • Report
  • January 2023
  • 146 Pages
  • North America
From
Europe Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - Product Thumbnail Image

Europe Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis

  • Report
  • January 2023
  • 153 Pages
  • Europe
From
Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Pharmacotherapy and Disease Type - Product Thumbnail Image

Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Pharmacotherapy and Disease Type

  • Report
  • October 2022
  • 209 Pages
  • Global
From
Urinary Incontinence (Genitourinary Disorders) - Drugs in Development, 2021 - Product Thumbnail Image

Urinary Incontinence (Genitourinary Disorders) - Drugs in Development, 2021

  • Drug Pipelines
  • March 2021
  • Global
From
  • 9 Results (Page 1 of 1)
Loading Indicator

Fesoterodine is a drug used to treat overactive bladder (OAB) and other urological disorders. It is a muscarinic receptor antagonist, meaning it works by blocking the action of a certain chemical in the body that causes bladder contractions. Fesoterodine is available in both immediate-release and extended-release formulations. The immediate-release formulation is taken twice daily, while the extended-release formulation is taken once daily. Common side effects of fesoterodine include dry mouth, constipation, and blurred vision. Fesoterodine is a relatively new drug, having been approved by the US Food and Drug Administration in 2008. It is used to treat OAB symptoms such as urinary urgency, frequency, and urge incontinence. It is also used to treat other urological disorders such as urinary retention and neurogenic bladder. Some companies in the fesoterodine market include Astellas Pharma, Inc., Allergan, Inc., and Teva Pharmaceuticals. Show Less Read more